Dr Nathan Karl Maeser, MD | |
1157 N 300 W, Suite 303, Provo, UT 84604-6124 | |
(801) 357-4547 | |
Not Available |
Full Name | Dr Nathan Karl Maeser |
---|---|
Gender | Male |
Speciality | Psychiatry |
Experience | 13 Years |
Location | 1157 N 300 W, Provo, Utah |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1659626430 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2084P0800X | Psychiatry & Neurology - Psychiatry | 9692048-1205 (Utah) | Primary |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Intermountain Healthcare Services, Inc | 1850209420 | 3063 |
News Archive
The Obama administration is targeting programs that help the poor and unemployed as it seeks to recover billions of dollars in improper payments. The effort, part of a government-wide focus on wasteful spending led by Vice President Biden, will get a high-profile boost today when the entire Cabinet meets for the first time on that subject alone.
Using skin cells from young patients who have a severe genetic heart defect, Stanford University School of Medicine scientists have generated beating heart cells that carry the same genetic mutation. The newly created human heart cells - cardiomyocytes - allowed the researchers for the first time to examine and characterize the disorder at the cellular level.
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced positive top-line results of the APEX-PD Phase III clinical study with IPX066 in Parkinson's disease (PD). IPX066 is a novel extended release carbidopa-levodopa product.
Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.
› Verified 7 days ago
Entity Name | Ihc Health Services Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1942325154 PECOS PAC ID: 1850209420 Enrollment ID: O20080610000303 |
News Archive
The Obama administration is targeting programs that help the poor and unemployed as it seeks to recover billions of dollars in improper payments. The effort, part of a government-wide focus on wasteful spending led by Vice President Biden, will get a high-profile boost today when the entire Cabinet meets for the first time on that subject alone.
Using skin cells from young patients who have a severe genetic heart defect, Stanford University School of Medicine scientists have generated beating heart cells that carry the same genetic mutation. The newly created human heart cells - cardiomyocytes - allowed the researchers for the first time to examine and characterize the disorder at the cellular level.
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced positive top-line results of the APEX-PD Phase III clinical study with IPX066 in Parkinson's disease (PD). IPX066 is a novel extended release carbidopa-levodopa product.
Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.
› Verified 7 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Nathan Karl Maeser, MD 1157 N 300 W, Suite 303, Provo, UT 84604-6124 Ph: (801) 357-4547 | Dr Nathan Karl Maeser, MD 1157 N 300 W, Suite 303, Provo, UT 84604-6124 Ph: (801) 357-4547 |
News Archive
The Obama administration is targeting programs that help the poor and unemployed as it seeks to recover billions of dollars in improper payments. The effort, part of a government-wide focus on wasteful spending led by Vice President Biden, will get a high-profile boost today when the entire Cabinet meets for the first time on that subject alone.
Using skin cells from young patients who have a severe genetic heart defect, Stanford University School of Medicine scientists have generated beating heart cells that carry the same genetic mutation. The newly created human heart cells - cardiomyocytes - allowed the researchers for the first time to examine and characterize the disorder at the cellular level.
Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc., today announced positive top-line results of the APEX-PD Phase III clinical study with IPX066 in Parkinson's disease (PD). IPX066 is a novel extended release carbidopa-levodopa product.
Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class antibodies, today announced that it has raised $33 million in a Series C round of funding.
› Verified 7 days ago
Edward Leslie Kelly, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 Fax: 801-344-4225 | |
Brent L Griffin, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-4542 | |
Aaron William Sanders, DO Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 395 W Cougar Blvd Ste 601, Provo, UT 84604 Phone: 801-357-7525 | |
Sam J Coates, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1034 N 500 W, Provo, UT 84604 Phone: 801-357-4542 | |
Dr. Rodney A Cheal, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 | |
Ms. Madhumathy Gundlapalli, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1300 E Center St, Provo, UT 84606 Phone: 801-344-4400 | |
Dr. Stephen Peters, PSYD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 1157 N 300 W, Provo, UT 84604 Phone: 801-357-1200 |